MTSR Metsera, Inc.

Nasdaq metsera.com


$ 85.75 $ 1.55 (1.9 %)    

Friday, 07-Nov-2025 19:43:35 EST
QQQ $ 612.14 $ 1.56 (0.26 %)
DIA $ 470.45 $ 1.64 (0.35 %)
SPY $ 672.31 $ 2.95 (0.44 %)
TLT $ 89.45 $ -0.19 (-0.21 %)
GLD $ 367.77 $ 0.35 (0.1 %)
$ 83.18
$ 81.50
$ 79.75 x 2
$ 89.35 x 56
$ 80.30 - $ 83.86
$ 12.30 - $ 83.86
1,923,331
na
8.72B
$ 2.46
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-28-2025 06-30-2025 10-Q
2 05-12-2025 03-31-2025 10-Q
3 03-26-2025 12-31-2024 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 pfizer-clinches-10-billion-deal-to-buy-obesity-drug-maker-metsera-outbidding-novo-nordisk-in-fierce-battle-for-weight-loss-market-dominance

Nvidia CEO Jensen Huang cautioned Elon Musk against underestimating the challenges of semiconductor manufacturing, saying build...

 pfizer-to-raise-metsera-bid-after-court-denies-attempt-to-block-rival-deal

Delaware court denies Pfizer bid to block Metsera's Novo Nordisk deal as FTC flags antitrust risks and Pfizer prepares a hi...

Core News & Articles

https://www.ft.com/content/52216b29-9f22-4338-85a7-eacfc33103a1

Core News & Articles

https://www.ft.com/content/ae3297f3-4dd1-4c8a-b9c5-9c3717d34c52 

Core News & Articles

"Metsera is gratified by the Delaware Court of Chancery's decision to deny Pfizer's request for a temporary restrai...

Core News & Articles

-Reuters Citing FTC Letter To Metsera

Core News & Articles

-Reuters Citing Metsera Letter To Court

Core News & Articles

-Reuters Citing Letter To Court

 novo-pfizer-are-battling-to-buy-the-future-of-weight-loss--but-viking-already-owns-it

Viking Global's $45 million investment in Metsera, a biotech company is caught in a bidding war between Pfizer and Novo Nor...

 pfizer-novo-nordisk-intensify-fight-for-metsera-as-buyout-offers-continue-to-climb

Novo Nordisk boosts its Metsera bid to $62.20 per share, valuing the company at $10 billion and outbidding Pfizer in the escala...

Core News & Articles

-Reuters Citing Conf. Call

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION